HRH The Princess Royal officially opened the BBSRC National Vaccinology Centre: The Jenner Building today (24 March, 2017) – a world leading vaccine development facility, located at The Pirbright Institute in Surrey.
The Pirbright Institute is to play a key role in a new international project funded by the European Commission, to fight the mosquito-transmitted diseases now threatening Europe.
The Infravec2 Project is an international consortium of 24 partner institutions coordinated by the Institut Pasteur, Paris.
A student studying for his PhD at The Pirbright Institute was named Young Innovator of the Year at the Guildford Innovation Awards 2017 on 22 February 2017. Tom Whitehead won the award for his research on egg anti-viral proteins which could lead to a major step forward in vaccine production rates.
The American Association for the Advancement of Science (AAAS) has selected a senior scientist at The Pirbright Institute as a 2017-2018 AAAS Alan I. Leshner Leadership Institute Public Engagement Fellow.
Scientists at The Pirbright Institute have used genetic engineering to develop a more efficient and effective vaccine for Marek’s disease which could pave the way for a new generation of poultry disease vaccines.
The Pirbright Institute is one of the largest recipients of the Government’s new £120 million fund to fight deadly diseases – winning £1.580 million with its partners, for a joint project to develop a safe and effective livestock vaccine against Rift Valley fever.
Studies assessing the effectiveness of anti-viral treatments for swine flu and those seeking to understand the behaviour of the virus, must factor in the route of infection during experiments, as this has a greater impact on results than previously thought, a new study from The Pirbright Institute has found.
Influenza A virus (IAV) is a global health threat. The infection in pigs causes severe disease when combined with other respiratory pathogens, and can result in considerable economic losses to farmers, and poses a significant risk to humans too.
Scientists at The Pirbright Institute have been encouraged by the results from a potential new vaccine candidate against Marek’s disease (MD). Using a recombinant (new combinations of genetic material) adenovirus which carries a single gene from a virulent strain of Marek’s disease virus, they are hopeful that further research and trials could lead to the production of an effective MD vaccine that is cheaper and easier to produce - and crucially has no possibility of reverting to a virulent strain.
The full potential of genetic modification or GM technology to tackle some of the world’s most dangerous diseases is still not being realised well over a decade after it was first developed. The lack of effective international regulation, regional variations in public opinion and uncertainties about the long-term effects are all hindering progress, say scientists from The Pirbright Institute, in a new discussion paper.
A large delegation from The Pirbright Institute will be flying the flag for great British science this week, at the biggest ever entomology conference.